DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IDAMYCIN

« Back to Dashboard

Clinical Trials for Idamycin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002812	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002812	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia	Completed	Children's Oncology Group	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002816	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002816	Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
NCT00002833	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002835	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.

Clinical Trial Conditions for Idamycin

Condition Name

Condition Name for Idamycin
Intervention	Trials
Leukemia	13
Acute Myeloid Leukemia	5
Acute Myelogenous Leukemia	3
Untreated Adult Acute Myeloid Leukemia	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Idamycin
Intervention	Trials
Leukemia	24
Leukemia, Myeloid	17
Leukemia, Myeloid, Acute	16
Preleukemia	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Idamycin

Trials by Country

Trials by Country for Idamycin
Location	Trials
United States	149
Canada	15
Australia	7
Netherlands	2
Switzerland	2

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Idamycin
Location	Trials
Texas	19
Missouri	6
Washington	6
New York	6
California	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Idamycin

Clinical Trial Phase

Clinical Trial Phase for Idamycin
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	13
Phase 1/Phase 2	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Idamycin
Clinical Trial Phase	Trials
Recruiting	11
Completed	10
Not yet recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Idamycin

Sponsor Name

Sponsor Name for Idamycin
Sponsor	Trials
M.D. Anderson Cancer Center	14
National Cancer Institute (NCI)	7
Children's Oncology Group	4

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Idamycin
Sponsor	Trials
Other	22
Industry	10
NIH	7

Export unavailable in trial.
Subscribe for complete access.